KORU Medical Systems, Inc. Appoints Eric Schiller as Chief Technology Officer
MWN-AI** Summary
KORU Medical Systems, Inc. (NASDAQ: KRMD) has appointed Eric Schiller as its new Chief Technology Officer, effective December 29, 2025. Schiller brings over 25 years of extensive leadership experience in research and development, device engineering, and product lifecycle management within the medical technology industry. In his role, he will be responsible for steering KORU's product development and innovation pipeline, while aligning technology strategies with the evolving needs of the company’s global customer base.
Schiller joins KORU from Sanofi, where he served as Global Head of Device Development Portfolio. His tenure at Sanofi involved building teams and advancing innovative delivery platforms, overseeing more than 80 pipeline assets aimed at specialty care and general medicine. Prior to that, he worked at Bristol-Myers Squibb and Celgene, supporting the launch of major immunology and hematology products that required sophisticated delivery systems. His engineering background includes significant roles at Becton Dickinson and Saint-Gobain, where he contributed to the development of next-generation syringe platforms and quality improvement initiatives.
KORU Medical's CEO, Linda Tharby, expressed confidence in Schiller's ability to enhance the company's innovative edge and competitive position in the market. Schiller himself emphasized the excitement surrounding KORU's growth trajectory and mission to improve patient quality of life through innovative subcutaneous drug delivery solutions. KORU's flagship products include the Freedom Syringe Infusion System, which allows for both self-administration at home and professional use in clinical settings.
For more information, visit KORU Medical's website at www.korumedical.com.
MWN-AI** Analysis
KORU Medical Systems, Inc. (NASDAQ: KRMD) stands at an intriguing juncture following the recent appointment of Eric Schiller as Chief Technology Officer, effective December 29, 2025. Schiller's extensive experience across research, device engineering, and product lifecycle management positions him to significantly impact KORU's innovative edge in the medical technology sector, particularly in large volume subcutaneous infusion solutions.
From a strategic standpoint, Schiller's background at Sanofi, which includes overseeing a broad portfolio and spearheading numerous launch initiatives, aligns well with KORU’s mission to enhance patient quality of life through innovation. His proven track record—reflected in his patent contributions and leadership in complex injection systems—suggests that he can enhance KORU's research and development capabilities while facilitating a robust product innovation pipeline. This is particularly timely as the medical technology landscape increasingly emphasizes patient-centric solutions and technology-driven processes.
Investors should view Schiller’s appointment as a bullish signal for KORU’s growth trajectory. His expertise can potentially strengthen KORU's competitive positioning amid rising demand for personalized healthcare solutions. Moreover, Schiller's focus on aligning technology strategy with market demands suggests proactive adaptation, possibly translating to improved financial performance and shareholder value.
Furthermore, the push for innovative delivery systems, like KORU's Freedom Syringe Infusion System, suggests a broad utility across various therapeutic areas, which could attract partnerships within the pharma sector. This capability aligns well with the industry's trend toward integrated drug-device combinations, positioning KORU favorably for collaborative ventures and clinical trials.
As KORU continues along this growth path, investors should monitor developments closely, particularly Schiller's initiatives in advancing R&D and enhancing strategic partnerships, as these factors are likely to significantly influence the company’s future performance in the medical technology market.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on developing, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced the appointment of Eric Schiller as Chief Technology Officer, effective December 29, 2025.
Eric joins KORU Medical with more than 25 years of leadership experience across research & development, device engineering, drug–device combination product development, supply chain strategy, and end-to-end product lifecycle management. As Chief Technology Officer, Eric will lead KORU’s product development and innovation pipeline and help shape the Company’s long-term technology and platform strategy, leveraging his experience to integrate portfolio planning with the evolving needs of KORU’s growing global customer base. He most recently served as Global Head of Device Development Portfolio at Sanofi, where he built and led a global team, advanced connected and reusable delivery platforms, drove multiple regulatory and launch-readiness initiatives, and oversaw more than 80 pipeline assets across Specialty Care, General Medicine and Vaccines.
Prior to Sanofi, Eric spent more than a decade at Bristol-Myers Squibb and Celgene in roles spanning device development, biologics commercialization, and global product strategy, where he supported launches for major immunology and hematology assets including therapies requiring complex injection and infusion delivery systems, and implemented programs that improved reliability, patient adherence, and supply continuity. His earlier engineering career at Becton Dickinson and Saint-Gobain included development of next-generation syringe platforms and quality, safety, and process-improvement initiatives.
Mr. Schiller holds an MBA with a management concentration from Seton Hall University and a Bachelor of Science in Mechanical Engineering from the New Jersey Institute of Technology. He is an inventor on more than a dozen U.S. patents in injection devices, safety systems, and drug-delivery components.
“As we continue to scale our business and expand into new therapeutic applications, Eric will bring expertise in senior technology leadership that aligns product innovation with the rapidly evolving needs of the market. Eric is an exceptional leader, who has built great teams, and his depth of experience in devices, engineering, and chemistry manufacturing and controls will be invaluable as we advance our platform strategy,” said Linda Tharby, CEO of KORU Medical Systems. “His strategic mindset, enterprise-level portfolio leadership, and passion for patient-centered innovation make him an ideal fit for KORU at this stage of our growth as we expand our pipeline and strengthen our competitive position.”
Mr. Schiller added, “KORU is at an exciting inflection point in its growth story, with a clear mission to enhance patient quality of life through innovation in subcutaneous drug delivery. I am energized to partner with the team to advance our next-generation platforms, accelerate our R&D capabilities, and drive a robust technology strategy that supports both near-term execution and long-term growth for patients, providers, and our pharmaceutical partners.”
About KORU Medical Systems
KORU Medical Systems develops, manufactures, and commercializes innovative and patient-centric large volume subcutaneous infusion solutions that improve quality of life for patients around the world. The Freedom Syringe Infusion System (“the Freedom System”) currently includes the Freedom60® and FreedomEdge® Syringe Infusion Drivers, Precision Flow Rate Tubing™ and HigH-Flo Subcutaneous Safety Needle Sets™. The Freedom System, which received its first FDA clearance in 1994, is used for self-administration in the home by the patient and/or delivery in an ambulatory infusion center by a healthcare professional. Through its Pharma Services and Clinical Trials business, KORU Medical provides products for use by biopharmaceutical companies in feasibility/clinical trials during the drug development process and, as needed, is capable of customizing the Freedom System for clinical and commercial use across multiple drug categories. For more information, please visit www.korumedical.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20251216783401/en/
Investor Contact:
Louisa Smith
investor@korumedical.com
FAQ**
How do Eric Schiller's extensive experiences, especially in drug-device combination development, position KORU Medical Systems Inc. (KRMD) for future innovations in large volume subcutaneous infusion technology?
In what ways does KORU Medical Systems Inc. (KRMD) plan to leverage Eric Schiller's strategic mindset to enhance its competitive positioning in the rapidly evolving medical technology market?
What specific initiatives and strategies will KORU Medical Systems Inc. (KRMD) pursue to integrate Eric Schiller’s technology leadership into their existing product development and innovation pipeline?
How does KORU Medical Systems Inc. (KRMD) envision the impact of Eric Schiller's appointment on the advancement of their Freedom Syringe Infusion System and overall growth trajectory in the coming years?
**MWN-AI FAQ is based on asking OpenAI questions about KORU Medical Systems Inc. (NASDAQ: KRMD).
NASDAQ: KRMD
KRMD Trading
0.89% G/L:
$4.54 Last:
69,872 Volume:
$4.46 Open:
